Randomized Study to Compare Immunogenicity and Safety of Seqirus* Quadrivalent Inactivated Influenza Vaccine With a US-Registered Influenza Vaccine in Pediatric Subjects Aged 5 to 17 Years | Zendy

AI Assistant Blog Pricing

Randomized Study to Compare Immunogenicity and Safety of Seqirus* Quadrivalent Inactivated Influenza Vaccine With a US-Registered Influenza Vaccine in Pediatric Subjects Aged 5 to 17 Years

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.